A review on pharmacokinetics, pharmacodynamics and clinical aspects of remdesivir and favipiravir for the treatment of Coronavirus disease
Journal of Drug Delivery and Therapeutics
; 11(1):121-129, 2021.
Article
in English
| CAB Abstracts | ID: covidwho-1409925
ABSTRACT
The coronavirus disease has spread all over the world. Till now no medicine, vaccine, and any other monoclonal antibodies have been approved for the diagnosis or prevention of COVID-19. In many countries, doctors are considering "repurposing" different approved drugs like interferon-a, lopinavir/ritonavir, ribavirin, and chloroquine phosphate, etc. to treat COVID-19. Remedesivir (GS-5734) is a prodrug of monophosphoramidate of adenosine analogue. Remedesivir block the viral RNA dependent RNA polymerease (RdRp). Favipiravir (T-705) is also a prodrug and was revealed during evaluating the antiviral activity of chemical agents concerning the influenza virus. This review summarizes the status, mechanisms, preclinical research, and clinical trial progress of remedesivir and favipiravir for the treatment of COVID-19.
Full text:
Available
Collection:
Databases of international organizations
Database:
CAB Abstracts
Type of study:
Prognostic study
Language:
English
Journal:
Journal of Drug Delivery and Therapeutics
Year:
2021
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS